{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:32:31Z","timestamp":1789237951559,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejphar.2025.177991","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T06:42:17Z","timestamp":1753425737000},"page":"177991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Safety profile of nivolumab-relatlimab in cancer patients: a living pharmacovigilance study of clinical trials and postmarketing data (version 1.0)"],"prefix":"10.1016","volume":"1004","author":[{"given":"Jianhong","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengmi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0870-382X","authenticated-orcid":false,"given":"Junyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177991_bib1","article-title":"Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation","volume":"387","author":"Akl","year":"2024","journal-title":"BMJ"},{"issue":"7934","key":"10.1016\/j.ejphar.2025.177991_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.ejphar.2025.177991_bib3","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.22.02072","article-title":"Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1\/programmed death ligand 1 therapy: results from the phase I\/IIa RELATIVITY-020 trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.177991_bib4","article-title":"Prophylaxis against covid-19: living systematic review and network meta-analysis","volume":"373","author":"Bartoszko","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2025.177991_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2023.04.010","article-title":"Activity and safety of first-line treatments for advanced melanoma: a network meta-analysis","volume":"188","author":"Boutros","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.ejphar.2025.177991_bib6","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1111\/cas.16205","article-title":"LAG-3 : recent developments in combinational therapies in cancer","volume":"115","author":"Chavanton","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejphar.2025.177991_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.ejphar.2025.177991_bib8","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","article-title":"Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial","volume":"30","author":"de Gooyer","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2025.177991_bib9","first-page":"1","article-title":"Double trouble: immunotherapy doublets in melanoma-approved and novel combinations to optimize treatment in advanced melanoma","volume":"42","author":"Dimitriou","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.ejphar.2025.177991_bib10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction- GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177991_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00403-024-03579-9","article-title":"The efficacy and safety of relatlimab\/nivolumab combination therapy in patients with advanced melanoma: a systematic review","volume":"317","author":"Hasanzadeh","year":"2024","journal-title":"Arch. Dermatol. Res."},{"issue":"17","key":"10.1016\/j.ejphar.2025.177991_bib12","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.23.01636","article-title":"First-line nivolumab and relatlimab plus chemotherapy for gastric or gastroesophageal junction a: the phase II RELATIVITY-060 study","volume":"42","author":"Hegewisch-Becker","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177991_bib13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177991_bib14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177991_bib15","article-title":"Overall survival and response with nivolumab and relatlimab in advanced melanoma","volume":"2","author":"Long","year":"2023","journal-title":"N. Engl. J. Med. Evid."},{"issue":"12","key":"10.1016\/j.ejphar.2025.177991_bib16","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/S1470-2045(24)00528-X","article-title":"Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study","volume":"25","author":"Miller","year":"2024","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177991_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008689","article-title":"Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"12","author":"Overman","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.ejphar.2025.177991_bib18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","article-title":"Nivolumab plus relatlimab: first approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ejphar.2025.177991_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2024.03.006","article-title":"Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?","volume":"35","author":"Pourmir","year":"2024","journal-title":"Ann. Oncol."},{"issue":"6382","key":"10.1016\/j.ejphar.2025.177991_bib20","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.ejphar.2025.177991_bib21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.ejphar.2025.177991_bib22","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41591-024-02965-0","article-title":"Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial","volume":"30","author":"Schuler","year":"2024","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177991_bib23","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"10.1016\/j.ejphar.2025.177991_bib24","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177991_bib25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ejphar.2025.177991_bib27","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejphar.2025.177991_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101535","article-title":"Toxicity spectrum of immunotherapy in advanced lung cancer: a safety analysis from clinical trials and a pharmacovigilance system","volume":"50","author":"Yan","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ejphar.2025.177991_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"eClinicalMedicine"},{"issue":"9","key":"10.1016\/j.ejphar.2025.177991_bib30","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925007459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925007459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T02:27:28Z","timestamp":1757644048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925007459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":29,"alternative-id":["S0014299925007459"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177991","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profile of nivolumab-relatlimab in cancer patients: a living pharmacovigilance study of clinical trials and postmarketing data (version 1.0)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177991"}}